Together, Taking on Cancer’s Toughest Challenges

Joan Neuner, MD, MPH

PROGRAM OVERVIEW

mcw.edu/departments/cancer-center @MCWCancerCenter
CPO PROGRAM CO-LEADERS

Ann Nattinger, MD, MPH
Senior Associate Dean for Research
Lady Riders Professor of Breast Cancer Research
Professor of Medicine
• Program Theme Focus: To improve cancer outcomes and reduce cancer disparities.
• Expertise: Breast cancer quality of care, survivorship care
• Federal funding since 1991

Joan Neuner, MD, MPH
Associate Professor, Department of Medicine
• Program Theme Focus: Cancer disparities
• Expertise: Medication adherence, pharmaceutical policy and disparities
• Federal funding since 2003
CPO PROGRAM

• Interrelated themes of improving cancer control and reducing cancer disparities
  • To identify and address processes that affect cancer control, such as cancer care access, quality and value.
  • To determine mechanisms of cancer disparities and develop novel interventions.
  • Capitalizes on historic MCW strengths in cancer treatment delivery and survivorship, and strong collaborations studying obesity, exercise, and screening.
Surgical volume is associated with lower morbidity surgical treatment

| L. Pezzin, T. Yen, A. Nattinger Collaboration  
Physician/Hospital Breast Cancer Treatment Volumes and Morbidity |

| TABLE 3 |

<table>
<thead>
<tr>
<th>SLNB Only (N = 3889) (51%)</th>
<th>SLNB to ALND (N = 3015) (39%)</th>
<th>ALND Only (N = 782) (10%)</th>
<th>Overall Cohort (N = 7686)</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. nodes removed</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>2.8 (2.5)</td>
<td>4.4 (4.5)</td>
<td>11.7 (6.8)</td>
</tr>
<tr>
<td>Median (Q1–Q3)</td>
<td>2 (1–3)</td>
<td>3 (2–5)</td>
<td>11 (7–16)</td>
</tr>
<tr>
<td>Lymph node category [n (%)]</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1–5</td>
<td>3535 (91)</td>
<td>2276 (76)</td>
<td>150 (19)</td>
</tr>
<tr>
<td>6–10</td>
<td>280 (7)</td>
<td>441 (15)</td>
<td>207 (26)</td>
</tr>
<tr>
<td>11–15</td>
<td>56 (1.4)</td>
<td>196 (6)</td>
<td>211 (27)</td>
</tr>
<tr>
<td>16+</td>
<td>18 (0.5)</td>
<td>102 (3)</td>
<td>214 (27)</td>
</tr>
<tr>
<td>5-year estimated lymphedema probability (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Estimated excess lymphedema probability (%)</td>
<td>11.0</td>
<td>150 (19)</td>
<td>5961 (78)</td>
</tr>
<tr>
<td>No. estimated lymphedema patients</td>
<td>0</td>
<td>428</td>
<td>5961</td>
</tr>
<tr>
<td>No. estimated excess lymphedema patients</td>
<td>425</td>
<td>221</td>
<td>1068</td>
</tr>
</tbody>
</table>

---

1 Estimated excess lymphedema probability = lymphedema probability minus the baseline 11.0% estimated lymphedema probability of SLNB only group.
2 Number of estimated lymphedema patients = total number of patients x estimated lymphedema probability.
3 Number of estimated excess lymphedema patients = total number of patients x estimated excess lymphedema probability.
4 ALND indicates axillary lymph node dissection; Q, quartile; SLNB, sentinel lymph node biopsy.
Beginning examination of NY state surgeon volume regulations on mortality
• I want to get off of [imatinib] just to feel normal again.... I think the nausea and the energy are the two things that are very annoying. [Patient 5]

• I would be able to stay on [imatinib] because I know what the side effects are, and I can certainly live with them. [Patient 12]
Patient reports independently predict survival after BMT.
In the HLA-matched setting the youngest donor should be prioritized.
M. Dellinger
Mercury, Polychlorinated Biphenyls, Selenium, and Fatty Acids in Tribal Fish Harvests of the Upper Great Lakes
Risk Anal, 2018
M. Dellinger

Mercury, Polychlorinated Biphenyls, Selenium, and Fatty Acids in Tribal Fish Harvests of the Upper Great Lakes

*Risk Anal, 2018*
Program Updates

Grants

Ann Nattinger/Liliana Pezzin, NCI R01: Can Regionalization Improve Outcomes and Reduce Disparities Related to Breast Cancer Care? An Evaluation of the NY Medicaid regionalization experiment

Matthew Dellinger, NIEHS R01: Gigiigooinaan (Our Fish): A New Advisory to Promote Anishinaable Health and Wellness

Alan Nyitray, NCI R01: Determining the Accuracy of Self- and Partner Anal Exams for Detecting Anal Abnormalities

Alan Nyitray, NCI R01: Annual Anal Sampling Using DNA Screening to Identify Men Who Have Sex With Men at Increased Risk for Anal Cancer

Melinda Stolley, NCI R01: Men Moving Forward: A Lifestyle Intervention for African American Prostate Cancer Survivors
CPO PROGRAM SPEAKERS

Kirsten Beyer, PhD, MPH
“Breast Cancer, Race and Place”

Melinda Stolley, PhD
“Obesity, Lifestyle Interventions and Cancer Survivorship”

Alan Nyitray, PhD
“Novel Opportunities for Anal Cancer Screening Among Men”